Physician profile
Angela A Below
NPI 1093709990
$2,027.11
in general payments reported to CMS, 2019-2025
27 companies · $521 in 2025
The $521 reported for 2025 was more than what 94% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $12.50 · 2021: $50.20 · 2022: $223 · 2023: $355 · 2024: $527 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,402.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $338.83 | 2019-2024 | Jornay Pm |
| Kaleo, INC. | $338.25 | 2019-2024 | Auvi-Q |
| Corium, LLC | $302.70 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $244.68 | 2021-2025 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $102.03 | 2022-2025 | Bexsero, Rotarix |
| Collegium Pharmaceutical, INC. | $90.22 | 2025 | Jornay Pm |
| Cranial Technologies, INC | $66.60 | 2023-2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $63.86 | 2019-2022 | |
| Neos Therapeutics, LP | $59.16 | 2019-2023 | Adzenys Xr-Odt |
| Pfizer INC. | $42.41 | 2019-2025 | |
| Tris Pharma INC | $39.02 | 2022-2025 | Dyanavel Xr |
| Ars Pharmaceuticals Operations, INC. | $36.31 | 2025 | Neffy |
| Ucb, INC. | $34.69 | 2023-2024 | Briviact |
| Phadia US INC. | $33.79 | 2023-2024 | Immunocap |
| Rhythm Pharmaceuticals, INC. | $24.95 | 2024 | Imcivree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $23.79 | 2025 | Vykat Xr |
| Astrazeneca Pharmaceuticals LP | $23.06 | 2024 | Flumist Quadrivalent |
| Biomarin Pharmaceutical INC. | $19.92 | 2025 | Voxzogo 1.2mg |
| Seqirus USA INC | $19.69 | 2025 | Flucelvax |
| Novartis Pharmaceuticals Corporation | $19.10 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.26 | 2025 | |
| Sanofi Pasteur INC. | $17.44 | 2024 | |
| Genentech USA, INC. | $14.85 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.00 | 2019 | |
| Advanced Respiratory, INC | $13.64 | 2019 | |
| Sobi, INC | $13.25 | 2019 | |
| Merck Sharp & Dohme LLC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Below listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.